Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
BIAL - PORTELA & CA, S.A. has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These are distributed across 2 distinct examiners. MOU, LIYUAN is the busiest examiner, holding 1 pending office action.
The distribution of 2 pending office actions across 2 distinct art units indicates a range of technical classifications within the portfolio. Because the busiest examiner pending count is 1, the workload is shared between 2 distinct examiners. This distribution allows for a comparison of prosecution results across the 2 distinct art units. Practitioners may find that having different examiners for the pending workload provides various perspectives on the company's technologies. The presence of 2 distinct art units suggests that the company's filings are not limited to a specific specialized group.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOU, LIYUAN | 1 | 43.8% | +59.9% |
| SHAMEEM, GOLAM M | 1 | 86.7% | +15.9% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17694902 | NITROCATECHOL DERIVATIVES AS COMT INHIBITORS | SHAMEEM, GOLAM M | 15d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18201920 | TREATMENT REGIMENS FOR EARLY IDIOPATHIC PARKINSON'S DISEASE | MOU, LIYUAN | 85d overdue |
| 17694902 | NITROCATECHOL DERIVATIVES AS COMT INHIBITORS | SHAMEEM, GOLAM M | 15d |
| Art Unit | Apps |
|---|---|
| 1628 | 1 |
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18201920 | TREATMENT REGIMENS FOR EARLY IDIOPATHIC PARKINSON'S DISEASE | MOU, LIYUAN | 1628 | §103DP | Final Rejection | 85d overdue | Pending | May 25, 2023 |
| 17694902 | NITROCATECHOL DERIVATIVES AS COMT INHIBITORS | SHAMEEM, GOLAM M | 1621 | §112 | Final Rejection | 15d | Pending | Mar 15, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBIAL - PORTELA & CA, S.A. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Liyuan Mou has the most, with 1 of BIAL - PORTELA & CA, S.A.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
